These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 9052318

  • 1. An analysis of the predictive probability of the in vitro contracture test for determining susceptibility to malignant hyperthermia.
    Hopkins PM, Ellis FR, Halsall PJ, Stewart AD.
    Anesth Analg; 1997 Mar; 84(3):648-56. PubMed ID: 9052318
    [Abstract] [Full Text] [Related]

  • 2. Malignant hyperthermia (MH) diagnostics: a comparison between the halothane-caffeine- and the ryanodine-contracture-test results in MH susceptible, normal and control muscle.
    Hartung E, Koob M, Anetseder M, Schoemig P, Krauspe R, Hogrefe G, Engelhardt W.
    Acta Anaesthesiol Scand; 1996 Apr; 40(4):437-44. PubMed ID: 8738688
    [Abstract] [Full Text] [Related]

  • 3. [Diagnosis of malignant hyperthermia susceptibility. 1. The significance of in vitro susceptibility tests].
    Mortier W, Breucking E.
    Anaesthesist; 1993 Oct; 42(10):675-83. PubMed ID: 8250201
    [Abstract] [Full Text] [Related]

  • 4. Sources of variability in halothane and caffeine contracture tests for susceptibility to malignant hyperthermia.
    Ording H, Bendixen D.
    Eur J Anaesthesiol; 1992 Sep; 9(5):367-76. PubMed ID: 1396623
    [Abstract] [Full Text] [Related]

  • 5. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia Group.
    Ording H, Brancadoro V, Cozzolino S, Ellis FR, Glauber V, Gonano EF, Halsall PJ, Hartung E, Heffron JJ, Heytens L, Kozak-Ribbens G, Kress H, Krivosic-Horber R, Lehmann-Horn F, Mortier W, Nivoche Y, Ranklev-Twetman E, Sigurdsson S, Snoeck M, Stieglitz P, Tegazzin V, Urwyler A, Wappler F.
    Acta Anaesthesiol Scand; 1997 Sep; 41(8):955-66. PubMed ID: 9311391
    [Abstract] [Full Text] [Related]

  • 6. C1840-T mutation in the human skeletal muscle ryanodine receptor gene: frequency in northern German families susceptible to malignant hyperthermia and the relationship to in vitro contracture response.
    Steinfath M, Singh S, Scholz J, Becker K, Lenzen C, Wappler F, Köchling A, Roewer N, Schulte am Esch J.
    J Mol Med (Berl); 1995 Jan; 73(1):35-40. PubMed ID: 7633940
    [Abstract] [Full Text] [Related]

  • 7. Classification of malignant hyperthermia-equivocal patients by 4-chloro-M-cresol.
    Gilly H, Musat I, Fricker R, Bittner RE, Steinbereithner K, Kress HG.
    Anesth Analg; 1997 Jul; 85(1):149-54. PubMed ID: 9212139
    [Abstract] [Full Text] [Related]

  • 8. Predictive factors of the contracture test for diagnosing malignant hyperthermia in a Brazilian population sample: a retrospective observational study.
    de Mello JM, Andrade PV, Santos JM, Oliveira ASB, Vainzof M, do Amaral JLG, Almeida da Silva HC.
    Braz J Anesthesiol; 2023 Jul; 73(2):145-152. PubMed ID: 35835312
    [Abstract] [Full Text] [Related]

  • 9. Ryanodine contracture threshold times for diagnosis of malignant hyperthermia susceptibility: an experimental approach from a single laboratory.
    Weisshorn R, Wappler F, Fiege M, Gerbershagen MU, Kolodzie K, Alberts P, Horn EP, Schulte Am Esch J.
    J Clin Anesth; 2004 Aug; 16(5):353-7. PubMed ID: 15374556
    [Abstract] [Full Text] [Related]

  • 10. 4-Chloro-m-cresol test--a possible supplementary test for diagnosis of malignant hyperthermia susceptibility.
    Ording H, Glahn K, Gardi T, Fagerlund T, Bendixen D.
    Acta Anaesthesiol Scand; 1997 Sep; 41(8):967-72. PubMed ID: 9311392
    [Abstract] [Full Text] [Related]

  • 11. Results of in vitro contracture testing of both parents of malignant hyperthermia susceptible probands.
    Islander G, Bendixen D, Ranklev-Twetman E, Ording H.
    Acta Anaesthesiol Scand; 1996 May; 40(5):579-84. PubMed ID: 8792888
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Similar susceptibility to halothane, caffeine and ryanodine in vitro reflects pharmacogenetic variability of malignant hyperthermia.
    Ginz HF, Girard T, Censier K, Urwyler A.
    Eur J Anaesthesiol; 2004 Feb; 21(2):151-7. PubMed ID: 14977348
    [Abstract] [Full Text] [Related]

  • 16. [Ryanodine-induced contractures for the diagnosis of malignant hyperthermia susceptibility].
    Lenzen C, Roewer N, Scholz J, Rumberger E, Schulte am Esch J.
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1991 Dec; 26(8):459-63. PubMed ID: 1786306
    [Abstract] [Full Text] [Related]

  • 17. High-purity ryanodine and 9,21-dehydroryanodine for in vitro diagnosis of malignant hyperthermia in man.
    Wappler F, Roewer N, Lenzen C, Köchling A, Scholz J, Steinfath M, Schulte am Esch J.
    Br J Anaesth; 1994 Feb; 72(2):240-2. PubMed ID: 8110584
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Use of the caffeine-halothane contracture test for the diagnosis of malignant hyperthermia in Brazil.
    Sudo RT, Cunha LB, Carmo PL, Matos AR, Trachez MM, Cardoso LA, Aguiar MI, Abreu AV, Zapata-Sudo G.
    Braz J Med Biol Res; 2010 Jun; 43(6):549-56. PubMed ID: 20464345
    [Abstract] [Full Text] [Related]

  • 20. Multicentre evaluation of in vitro contracture testing with bolus administration of 4-chloro-m-cresol for diagnosis of malignant hyperthermia susceptibility.
    Wappler F, Anetseder M, Baur CP, Censier K, Doetsch S, Felleiter P, Fiege M, Fricker R, Halsall PJ, Hartung E, Heffron JJ, Heytens L, Hopkins PM, Klingler W, Lehmann-Horn F, Nivoche Y, Tegazzin V, Tzanova I, Urwyler A, Weisshorn R, Schulte am Esch J.
    Eur J Anaesthesiol; 2003 Jul; 20(7):528-36. PubMed ID: 12884985
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.